Diethylaniline

Diethylaniline

SCHEMBL184484

B.CCN(CC)c1ccccc1

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.67
CNR2 P34972 4/20 0.59
ALDH1A1 P00352 4/20 0.54
CYP3A4 P08684 2/20 0.54
PSMD14 O00487 1/20 0.54
MAPK1 P28482 1/20 0.54
RECQL P46063 1/20 0.54
GFER P55789 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
MEN1 O00255 2/20 0.53
RAB9A P51151 2/20 0.53
KMT2A Q03164 2/20 0.53
NPC1 O15118 1/20 0.53
NOX1 Q9Y5S8 1/20 0.53
ALDH3A1 P30838 1/20 0.50
ALDH1A3 P47895 1/20 0.50
TAAR1 Q96RJ0 2/20 0.48
GLA P06280 1/20 0.48
GAA P10253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Diethylaniline SCHEMBL26698928 1.00 TSHR (0.67) TSHRCNR2ALDH1A1CYP3A4PSMD14
Diethylaniline SCHEMBL28042549 0.97 TSHR (0.64) TSHRCNR2ALDH1A1CYP3A4PSMD14
Diethylaniline SCHEMBL17594 0.97 TSHR (0.70) TSHRCNR2ALDH1A1CYP3A4PSMD14
Diethylaniline SCHEMBL9000098 0.97 TSHR (0.70) TSHRCNR2ALDH1A1CYP3A4PSMD14
Diethylaniline SCHEMBL9638069 0.94 TSHR (0.67) TSHRCNR2ALDH1A1CYP3A4PSMD14
Diethylaniline SCHEMBL29597320 0.94 TSHR (0.67) TSHRCNR2ALDH1A1CYP3A4PSMD14
Diethylaniline SCHEMBL30880867 0.94 TSHR (0.67) TSHRCNR2ALDH1A1CYP3A4PSMD14
Diethylaniline SCHEMBL2215318 0.94 TSHR (0.67) TSHRCNR2ALDH1A1CYP3A4PSMD14
Diethylaniline SCHEMBL31229134 0.94 TSHR (0.67) TSHRCNR2ALDH1A1CYP3A4PSMD14
Diethylaniline SCHEMBL30768306 0.94 TSHR (0.67) TSHRCNR2ALDH1A1CYP3A4PSMD14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1056 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4613745-A2 PROCESS FOR PREPARING A COT INHIBITOR COMPOUND Gilead Sciences, Inc. (US) 2025-09-10 EP claimed
CN-119390681-A Process for preparing COT inhibitor compounds 吉利德科学公司 2025-02-07 CN claimed
US-20240150300-A1 S-CONFIGURATION-CONTAINING AMINO BENZAMIDE PYRIDAZINONE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2024-05-09 US claimed
EP-4296266-A1 S-CONFIGURATION-CONTAINING AMINO BENZAMIDE PYRIDAZINONE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2023-12-27 EP claimed
EP-4212533-A1 PROCESS FOR PREPARING PURINE DERIVATIVES Cyclacel Limited (GB) 2023-07-19 EP claimed
US-20230104823-A1 PROCESS FOR THE PREPARATION OF PURINE DERIVATIVES EXHIBITING CDK INHIBITORY ACTIVITY CYCLACEL LIMITED (GB) 2023-04-06 US claimed
EP-4126862-A1 PROCESS FOR PREPARING A COT INHIBITOR COMPOUND GILEAD SCIENCES, INC. (US) 2023-02-08 EP claimed
EP-3573988-B1 PROCESS FOR PREPARING PURINE DERIVATIVES CYCLACEL LTD (GB) 2022-12-28 EP claimed
EP-4093740-A1 PROCESS FOR THE PREPARATION OF PURINE DERIVATIVES EXHIBITING CDK INHIBITORY ACTIVITY Cyclacel Limited (GB) 2022-11-30 EP claimed
CN-115397824-A Process for preparing COT inhibitor compounds 吉利德科学公司 2022-11-25 CN claimed
EP-0979208-A4 COMPOSITION AND METHOD FOR REDUCING COPPER OXIDE TO METALLIC COPPER MORTON INT INC (US) 2000-10-25 EP claimed
US-6124503-A Processes for making and using alkylaminoarylcarbonyl compounds EASTMAN KODAK COMPANY (US) 2000-09-26 US claimed
US-6086956-A Composition and method for reducing copper oxide to metallic copper MORTON INTERNATIONAL INC. (US) 2000-07-11 US claimed
EP-0979208-A1 COMPOSITION AND METHOD FOR REDUCING COPPER OXIDE TO METALLIC COPPER MORTON INTERNATIONAL, INC. (US) 2000-02-16 EP claimed
WO-1999042402-A1 COMPOSITION AND METHOD FOR REDUCING COPPER OXIDE TO METALLIC COPPER MORTON INTERNATIONAL, INC. (US) 1999-08-26 WO claimed
US-5900186-A BONDING COPPER TO RESIN USING CYCLIC BORANE REDUCTING AGENT MORTON INTERNATIONAL, INC. (US) 1999-05-04 US claimed
EP-0680484-B1 OPTICALLY ACTIVE BETA-AMINOALKOXYBORANE COMPLEXES NISSAN CHEMICAL IND LTD (JP) 1998-08-19 EP claimed
US-5753309-A CYCLIC BORANE REDUCING AGENTS SURFACE TEK SPECIALTY PRODUCTS, INC. (US) 1998-05-19 US claimed
EP-0369545-B1 PROCESS FOR THE PREPARATION OF ELEMENTAL SOLS H.B.T. HOLLAND BIOTECHNOLOGY B.V. (NL) 1992-08-19 EP claimed
US-4243803-A Production of 7-(2-aminomethylphenylacetamido)-3-(1-carboxymethyltetrazol-5-ylthiomethyl)-3-cephem-4-carboxylic acid BRISTOL-MYERS COMPANY (US) 1981-01-06 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150300-A1 S-CONFIGURATION-CONTAINING AMINO BENZAMIDE PYRIDAZINONE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF HDAC11, HDAC1, HDAC10 TSHR 4094/4885CNR2 3765/4885ALDH1A1 764/4885
US-20230104823-A1 PROCESS FOR THE PREPARATION OF PURINE DERIVATIVES EXHIBITING CDK INHIBITORY ACTIVITY CDK9, CDK19, CDK7 TSHR 1130/4885CNR2 946/4885ALDH1A1 2936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.